A Phase 1 interventional study of Cisplatin in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-11-02.
Sponsored by Northwell Health · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing cisplatin in Ovarian Neoplasms — 7 open to participants now, 11 under way, 4 of them phase 3. Cisplatin · Ovarian Neoplasms.
Among the 51 studies testing cisplatin in Ovarian Neoplasms, this one is the 35th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 in phase 1, reaches primary completion later than 0 of the 10 other live ones, and was the 40th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →7 of the 51 studies testing cisplatin in Ovarian Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Women only
GOG Foundation · Sites in United States
Ages 18+ · Women only
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 18–80
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Fudan University · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 25 · Phase 3 9
First in 1994; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 43 across the 46 interventional studies. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 51 have an industry lead sponsor. The 10 most frequent:
Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.
Northwell Health has 1 study filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing cisplatin in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520074Phase 3Fudan UniversityAdjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | 2027-09 |
| NCT05415709Ohio State University Comprehensive Cancer CenterHyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | 2026-12-31 |
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
| NCT04491942National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies testing cisplatin in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The majority of women diagnosed with ovarian, fallopian tube and primary peritoneal cancer present with advanced stage III and IV disease. Despite aggressive surgery and systemic chemotherapy, the majority of patients will relapse. Five year survival remains only 20-35% for patients diagnosed with bulky stage IIIC and IV cancers. Patients who are not candidates for an initial cytoreductive surgery at the time of diagnosis form a particularly poor prognosis group. These patients are treated with neoadjuvant chemotherapy (NACT) and will ultimately undergo cytoreductive surgery provided there is a response to chemotherapy. New therapies for this cohort of women are urgently needed.
The investigators have designed a pilot study to evaluate the feasibility of heated intraoperative peritoneal chemotherapy (HIPEC) given at the time of interval cytoreductive surgery after 3 cycles of NACT. Patients undergoing NACT for ovarian, fallopian tube or primary peritoneal cancer will be evaluated after their third cycle of chemotherapy for trial participation. Patient meeting eligibility criteria will proceed with cytoreductive surgery. HIPEC will be administered in those patients in whom optimal tumor cytoreduction is achieved. Primary objective of this study is to evaluate the feasibility, toxicity and tolerability of HIPEC administered after NACT.
Cancer of the ovary, fallopian tube and peritoneum (referred to as epithelial ovarian cancer, EOC) remains the leading cause of death from gynecologic cancer in the US and is expected to account for 22,000 cases and 14,000 deaths in 2016. Patients classically present with peritoneal carcinomatosis and ascites, a reflection of the dissemination pattern of this cancer in the peritoneal cavity. Malignant cells in EOC disseminate throughout the peritoneal cavity forming tumors on the parietal and visceral peritoneum. The majority of patients will be found to have advanced International Federation of Gynecology and Obstetrics (FIGO) stage III and IV disease at initial presentation. Patients with peritoneal carcinomatosis from EOC most often succumb to advanced locoregional disease in the form of intractable ascites, malignant visceral obstruction and cancer cachexia.
Primary cytoreductive surgery (PCS) followed by systemic chemotherapy has been the standard of care for women presenting with advanced EOC. The ability to achieve optimal surgical cytoreduction is historically the most important prognostic factor for women with EOC. The Gynecologic Oncology Group defines optimal cytoreduction as a post-operative residual disease of ≤ 1 cm in largest diameter . Wide variability in the extent and effort of cytoreductive surgery is seen in clinical practice with surgical cytoreductive efforts ranging from standard procedures (hysterectomy, salpingo-opherectomy, omentectomy) to complex multiviceral resections that may require radical upper abdominal surgery. There is increasing evidence that the patients who ultimately gain the most benefit from surgery are those with no gross residual disease (R0 resection) at the completion of PCS . An examination of 2,655 patients with epithelial ovarian cancer or primary peritoneal cancer enrolled in the Gynecologic Oncology Group 182 study demonstrated improved OS and PFS in those patients with in whom PCS resulted in a complete gross resection . Patients presenting with bulky upper abdominal disease (UAD) have a particularly poor prognosis. Women presenting with bulky UAD have been shown to have inferior PFS and OS survival compared to patents with no or limited UAD even among patients in whom optimal debulking surgery is successfully performed . Importantly, the presence of bulky UAD is associated with diminishing rates of successful PCS.
Advanced stage EOC is heterogenous, ranging from limited intra-abdominal disease to diffuse carcinomatosis involving the majority of the peritoneal surfaces. Use of a universal staging system for peritoneal malignancy may aid the clinician in treatment planning and prognostication. While several attempts have been made to develop peritoneal cancer scoring systems, the most widely used is the Peritoneal Cancer Index (PCI) as described by Jacquet and Sugarbaker in 1996 . The PCI quantitates the volume of tumor implants in 13 different abdomino-pelvic regions which are added up to form a score ranging from 0-39. While the PCI may be used as a prognostic indicator, it does not directly correlate with resectability of the disease. Tumor involvement of critical anatomic sites, for example regions 9, 10 and 11, representing the jejunum and ileum, may be associated with unresectable disease despite a low PCI score .
Two recently published randomized controlled trials demonstrated that neoadjuvant chemotherapy (NACT) and interval cytoreductive surgery (ICS) was non-inferior to PCS and adjuvant chemotherapy and resulted in a lower incidence of treatment related morbidity and mortality. These trials, however, have been criticized for lower optimal debulking rates and significantly lower median overall survival rates compared to prior trials in advanced EOC. The choice between PCS and NACT remains controversial and clinical guidelines have recently been published to aid clinicians in the choice between these treatment plans .
Patients who are not candidates for PCS due to medical comorbidities, poor performance status or clinically apparent or obvious unresectable disease constitute a group with a particularly poor prognosis. These patients are preferentially treated with neoadjuvant chemotherapy (NACT). NACT is associated with decreased peri-operative morbidity and an increased likelihood of optimal cytoreduction at surgery compared with primary surgery, however, to date a survival benefit or improvement has not been demonstrated . A recent multi-institutional observational study evaluating the use of NACT in patients with stage III/IV EOC at 6 NCI designated cancer centers demonstrated a significant increase in the use of NACT since 2010, from 16 - 34% in stage III and from 41 - 62% in stage IV EOC . Patients who received NACT were more likely to undergo optimal CRS but were less likely to require ICU admission or re-hospitalization. Among women with stage IIIC disease who had optimal CRS to ≤1 cm, NACT was associated with decreased overall survival when compared to PCS. This difference in survival, however, did not persist in NACT patients in whom CRS resulted in no gross residual disease.
Because of the tendency for EOC to remain confined within the peritoneal cavity for much of the course of disease, the use of post-operative intra-peritoneal (IP) chemotherapy has been extensively evaluated in women who have undergone successful cytoreductive surgery (CRS). Four large randomized clinical trials have been performed by the Gynecologic Oncology Group (GOG), three of which demonstrate improved overall survival in patients treated with an IP regimen. GOG 172 demonstrated a striking 16 month improvement in overall survival in patient's receiving IP cisplatin and paclitaxel when compared to patients receiving intravenous cisplatin and paclitaxel, a survival difference that was sustained in a follow-up publication after a median 10 year survival . Despite randomized controlled trial (RCT) evidence supporting a survival advantage for IP chemotherapy, its use remains low, largely due to potential toxicity and possible IP catheter complications. Despite optimal CRS and systemic chemotherapy the majority of patients will ultimately experience recurrence of the disease.
Heated intra-operative peritoneal chemotherapy (HIPEC) has garnered interest in the international oncology community for the treatment of peritoneal surface malignancies. HIPEC has demonstrated clinical efficacy for the treatment of pseudomyxoma peritonei, appendiceal cancer, colon cancer and malignant mesothelioma. HIPEC allows for the treatment of residual microscopic disease at the completion of CRS. HIPEC takes advantage of the plasma-peritoneal barrier to allow for peritoneal drug levels 20-1000 times that seen in plasma . HIPEC to >41°C may have anti-tumor effects as well as allow for better penetration of the drug into residual tumor . The use of HIPEC at the time of surgery, prior to the formation of adhesions, may allow for improved distribution of chemotherapy throughout the peritoneal cavity.
HIPEC has been investigated as a treatment for patients with newly diagnosed EOC as well as for patients with recurrent disease. Retrospective and case-control studies show a survival advantage for patients in both the primary and recurrent disease setting.
A recent randomized controlled study performed in Europe was the first well-designed, randomized, prospective clinical trial to demonstrate a survival advantage for HIPEC in EOC . This phase 3 randomized trial evaluated the administration of HIPEC using cisplatin in women undergoing interval cytoreductive surgery after NACT and demonstrated a significant improvement in progression free and overall survival with acceptable toxicity.
By far, the most common drug evaluated in HIPEC for EOC is Cisplatin. Cisplatin (CDDP) is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis- position. It has biochemical properties similar to that of bifunctional alkylating agents producing inter- and intra-strand cross-links in DNA. It is non-cell-cycle specific. Approximately 95% of the dose is absorbed from the peritoneal cavity in 1.0 hour. CDDP concentrates in the liver, kidney and intestine and is excreted by the kidneys. The dose of CDDP recommended for normothermic intraperitoneal administration is the same as that recommended for intravenous administration and ranges from 75 -100 mg/m2. The major dose-limiting toxicity of CDDP is dose-related cumulative renal insufficiency. Other toxicities include ototoxicity, myelosuppression, nausea and vomiting, hair loss and peripheral neuropathy.
A recent phase I multicenter trial of NACT followed by HIPEC in EOC using CDDP established a dose of 70 mg/m2 as a tolerable dose in patients who had received 6 cycles of carboplatin and paclitaxel neoadjuvant chemotherapy . The results of this recently published phase I clinical trial are encouraging. However, in current clinical practice, patients tend to receive 3 cycles of NACT with carboplatin and paclitaxel based regimens followed by CRS, as opposed to 6 initial cycles of NACT given in the phase I study.
The investigators propose a pilot study evaluating the feasibility of HIPEC in women undergoing interval CRS and achieving optimal tumor cytoreduction after 3 cycles of NACT. The safety, tolerability and efficacy of HIPEC will be evaluated in this cohort of EOC patients with historically inferior outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient must have documented disease limited to the abdomen and pelvis that is amenable to complete CRS indicated by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
Drug: Cisplatin
Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
Morbidity, assessed by the occurrence of adverse events and serious adverse events
Severity of adverse events will be evaluated using the NCI Common Terminology Criteria for Adverse Events version 4.0 \[NCI CTCAE v4.0\]. AEs will be classified as possibly, probably, or definitely related to study treatment.
Time frame: 30 days
Safety data obtained from scheduled exams
Physical examinations, vital signs, hematologic and clinical parameters, measured monthly for 12 months after initial study treatment or subject discontinuation, whichever comes first.
Time frame: 1 year
Mortality
Time from surgery date to death due to any cause.
Time frame: 5 years
Progression-free survival
Time from surgery date to the first documentation of disease progression or death due to any cause.
Time frame: 5 years
Ability to complete systemic IV chemotherapy after IDS and HIPEC
Patient completion of systemic IV chemotherapy after surgery and HIPEC.
Time frame: 1 year
Functional Assessment of Cancer Therapy-Ovarian (FACT-O)
Survey administered to assess for quality of life.
Time frame: 2 years
Completeness of surgical cytoreduction
Complete cytoreduction will be determined as having a CC score of 0 or 1
Time frame: 24 hours
Achievement of hyperthermia
Target intra-peritoneal temperature of 41-43°C.
Time frame: 24 hours
Plan to share: No
Started Mar 2019 (actual). Primary completion is estimated for Jul 2024, 63 months after the start.
Of 172 non-industry phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 63 months is above that.
Counting every sponsor, half of 382 studies reached it within 50 months; a quarter within 32 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cisplatin